sosei group corp
(4565:Tokyo Stock Exchange)
David Chiswell Ph.D.
|Age||Total Calculated Compensation||This person is connected to 23 board members in 2 different organizations across 6 different industries.|
See Board Relationships
Dr. David Chiswell, Ph.D., has been Chief Executive Officer at Kymab Limited since April 1, 2016 and served as its Chairman from September 2013 to April 1, 2016 and Interim Chief Executive Officer until April 1, 2016. Dr. Chiswell serves as Chairman of Albireo Pharma. He is an Advisor to a number of international private equity funds including BioComm in Melbourne, Australia. Dr. Chriswell was a Founder of Cambridge Antibody Technology, where he was responsible for operational ...
Kojimachi Tsuruya Hachiman BuildingPhone: 81 3 5210 3290
Tokyo, -- 102-0083
Fax: 81 3 5210 3291
Board Members Memberships*
Chairman of the Board
Education*There is no Education data available.
Annual Compensation*There is no Annual Compensation data available.
Stock Options*There is no Stock Options data available.
Total Compensation*There is no Total Compensation data available.
The information and data displayed in this profile are created and managed by Capital IQ, a Standard & Poor's company. Bloomberg.com does not create or control the content. For inquiries, please contact Capital IQ directly by clicking here.
|There is no Competitor Compensation data available.|
Sponsored Financial Commentaries
Only a company representative may request an update for the company profile. Documentation will be required.